Promise Bio
Epiproteomic Analyses on standard Mass-Spectrometry Data
Company Overview
Snapshot
Founded in January 2023 by Ronel Veksler, Promise Bio is a Health Tech & Life Sciences company with 11–50 employees. The company has raised $9 million across two funding rounds from two investors. In December 2024, Promise Bio emerged from stealth with an $8.3 million seed investment.
Business overview
Promise Bio is a Health Tech & Life Sciences company that develops precision medicine solutions for immune-mediated diseases. The company's core technology leverages post-translational modifications (PTM) and artificial intelligence to uncover unique biological insights from standard mass-spectrometry data. Its PROMISE platform uses proprietary Comprehensive PTM Profiling to detect up to 45 PTM types simultaneously, enabling the identification of functional biomarkers from diverse biological samples. Promise Bio partners with pharmaceutical companies to enhance data-driven discovery and support drug research and development.
Strategic signal
In February 2026, Promise Bio launched the Frontier Epiproteomic Innovation Grant, an R&D access initiative focused on translational epiproteomic analysis. This program signals the company's commitment to fostering innovation and collaboration within the epiproteomics field, potentially accelerating the development and adoption of its technology for precision medicine solutions.
Log in to access full profile ›Company Intelligence Q&A
- When was Promise Bio founded?
- Promise Bio was founded in January 2023.
- What is Promise Bio's primary focus?
- Promise Bio focuses on pioneering precision medicine solutions for immune-mediated diseases by harnessing post-translational modifications (PTM) and artificial intelligence.
- What was a significant funding event for Promise Bio?
- In December 2024, Promise Bio emerged from stealth with an $8.3 million seed investment, with.
- What is the Frontier Epiproteomic Innovation Grant?
- In February 2026, Promise Bio launched the Frontier Epiproteomic Innovation Grant, an R&D access initiative designed to promote translational epiproteomic analysis.
- Has Promise Bio received any non-equity funding?
- In January 2024, Promise Bio received a grant from the Israel Innovation Authority.